Sanofi

SNY

$44.66

+1.02%

N/A+$0.45

Healthcare

Drug Manufacturers - General

NASDAQ

Active Trading

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic ...

Recent News of SNY

Medical Product Outsourcing7/13/2026Bullish (0.411)

Enable Injections’ On-Body Injector Wins FDA Nod to Deliver Sanofi Anticancer Drug

Enable Injections' CirCLIQ on-body injector has received FDA approval for administering Sanofi's subcutaneous Sarclisa Escena for multiple myeloma patients. This makes Sarclisa Escena the first anticancer treatment approved in the U.S. for delivery via an on-body injector, offering comparable efficacy to intravenous infusion with shorter treatment times and fewer reactions. The innovation aims to improve the patient experience for those undergoing frequent treatments for multiple myeloma.

Idéal Investisseur7/13/2026Neutral (0.041)

Sanofi: FDA Approves Sarclisa Escena, First Cancer Drug via Portable Injector

The FDA has approved Sanofi's Sarclisa Escena, a subcutaneous formulation of Sarclisa, for the treatment of multiple myeloma. This marks the first cancer treatment to be administered via a portable on-body injector (Enable Injections' CirCLIQ), offering both this method and manual injection. The approval is supported by the IRAKLIA trial, which confirmed the non-inferiority and a favorable safety profile of the subcutaneous administration compared to intravenous infusion.

Simply Wall Street7/11/2026Somewhat-Bullish (0.315)

Sanofi (ENXTPA:SAN) Stock Looks Cheap On Earnings Yet Fairly Valued Overall

Sanofi's stock, despite a modest 7.5% return over five years, appears undervalued on its current P/E ratio of 18.9x compared to an industry average of 20.9x and a fair P/E of 36.4x. This suggests that the market is not fully pricing in the company's earnings potential, possibly due to concerns about execution risk with its pipeline and key products. The ongoing debate centers on whether this discount represents a mispricing opportunity or a reflection of persistent underlying risks.

Yahoo Finance7/11/2026Bullish (0.401)

Sanofi (ENXTPA:SAN) Could Be 21% Undervalued As FDA Clears Sarclisa Escena

Sanofi's stock may be 21% undervalued at €96.70 despite a recent 4.94% dip over 90 days and a 7.40% year-to-date decline. This undervaluation comes after the FDA approved Sarclisa Escena, a new subcutaneous multiple myeloma treatment, highlighting the company's strong R&D pipeline and innovative product launches. Analysts suggest Sanofi is well-positioned for long-term growth due to its focus on chronic disease treatments and expanding biologics, though risks like pricing pressure in vaccines exist.

Benzinga7/10/2026Bullish (0.408)

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

Sanofi received FDA approval for Sarclisa Escena, a wearable injector form of its blood cancer drug, making it the first anticancer therapy administrable via both on-body injector (OBI) and manual subcutaneous injection. This approval was based on Phase 3 data showing comparable efficacy and safety to the intravenous form, with reduced treatment time and infusion-related reactions. The new hands-free system, CirCLIQ, is expected to enhance patient treatment experience and streamline administration for healthcare providers.

Sanofi

Recent News of SNY

Enable Injections’ On-Body Injector Wins FDA Nod to Deliver Sanofi Anticancer Drug

Sanofi: FDA Approves Sarclisa Escena, First Cancer Drug via Portable Injector

Sanofi (ENXTPA:SAN) Stock Looks Cheap On Earnings Yet Fairly Valued Overall

Sanofi (ENXTPA:SAN) Could Be 21% Undervalued As FDA Clears Sarclisa Escena

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

Enable Injections’ On-Body Injector Wins FDA Nod to Deliver Sanofi Anticancer Drug

Sanofi: FDA Approves Sarclisa Escena, First Cancer Drug via Portable Injector

Sanofi (ENXTPA:SAN) Stock Looks Cheap On Earnings Yet Fairly Valued Overall

Sanofi (ENXTPA:SAN) Could Be 21% Undervalued As FDA Clears Sarclisa Escena

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

FDA approves Sanofi anticancer treatment delivered through Enable Injections on-body device

Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

Sanofi: Information concerning the total number of voting rights and shares - June 2026

US FDA approves Sanofi's wearable injector form of blood cancer drug

Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Sanofi: Information concerning the total number of voting rights and shares - June 2026

How Sanofi Deploys AI at Scale to Transform Medicine Journey

Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme

Sanofi offers EU commitments for flu vaccine disparagement claims

Commission seeks feedback on commitments offered by Sanofi over possible anticompetitive conduct regarding the promotion of a flu vaccine for vulnerable patients

Did Nexviazyme’s Baby-COMET Win and M1Pram Shift Just Reframe Sanofi’s (ENXTPA:SAN) Rare-Disease Focus?

Sanofi offers to stop disparaging CSL’s flu vaccine after EU probe

Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine

EU seeks advice on Sanofi's response to mismarketing claim

EU seeks feedback on Sanofi’s commitments addressing suspected anti-competitive behaviour

Sanofi to stop disparaging rival flu vaccine to stave off EU antitrust fine

Sanofi Stock 12‑Month Price Target Cut to $52.6, Implies 22% Upside

Wanted: More corporate sponsors. Here’s why Sanofi stepped up

Nexviazyme phase 3 success in infantile-onset Pompe at Sanofi (NASDAQ: SNY)

Genzyme Ireland’s 483 Is Not a Manufacturing Story. It’s a Sponsor Oversight Indictment.

SJP’s Sanofi at M Station West earns WELL platinum certification

SANOFI : Goldman Sachs is Neutral

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

French drugmaker commits to Cambridge headquarters years ahead of schedule

When Your Drug Supplier Gets a Warning Letter: What Genzyme Ireland Means for Trial Supply Planning

Availability of the aide-mémoire for Q2 2026 results

Sanofi announces phase 3 study data for infantile-onset Pompe disease

Sanofi unit in Ireland chided by FDA over manufacturing flubs linked to Altuviiio

SJP Properties’ Sanofi at M Station West earns WELL v2 Platinum Certification

Sanofi aims for Nexviazyme approval in younger Pompe disease patients

Sanofi aims for Nexviazyme approval in younger Pompe disease patients

Sanofi (ENXTPA:SAN) Stock May Be Undervalued As Fresh Drug Approval News Emerges

Sanofi eyes extending Nexviazyme into infantile Pompe

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

A New Chapter of Strategic Philanthropy – Sanofi Foundation

EAN 2026: Sanofi’s Cenrifki post hoc data suggests lesions may not indicate failure

EAN 2026: Sanofi’s Cenrifki post hoc data suggests lesions may not indicate failure

Cilcare Updates License Agreement with Sanofi, Brings Pharma Giant on as Equity Holder

Sanofi Wins $10.6 Million State Grant to Cut Emissions at Vaccine Plant

Capitol Roundup: Shapiro announces new RISE PA grant for Sanofi Pasteur in Monroe County

Gov. Shapiro speaks at Sanofi Pasteur, highlighting grant to lower emissions across the Commonwealth

Sanofi faces formal EU probe over campaign that allegedly disparaged CSL's rival flu shot

Sanofi Probed by EU Over Flu Vaccine Marketing

Sanofi under antitrust probe as European Commission kicks off formal proceedings